View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 5, 2020

Dynacure doses first patient in Unite-CNM study of DYN101

Drug development company Dynacure has dosed the first patient in the Phase I/II Unite-CNM study to evaluate investigational antisense medicine DYN101.

Drug development company Dynacure has dosed the first patient in the Phase I/II Unite-CNM study to evaluate investigational antisense medicine DYN101.

DYN101 is intended to modulate the expression of dynamin 2 (DNM2) for the treatment of Myotubular and Centronuclear Myopathies (CNM).

CNMs, which affect skeletal muscles from birth, are rare, life-threatening disorders. Around 5,000 patients are affected by the disease in the EU, US, Japan and Australia.

The multi-centre, ascending dose study, Unite-CNM (DYN101-C101), aims to examine the tolerability, safety, pharmacokinetics and preliminary efficacy of DYN101 in around 18 patients, above the age of 16 years, with X-linked (XLCNM) or autosomal dominant CNM (ADCNM).

The study will primarily focus on detecting an optimal dose of the drug. It will also access different domains of efficacy in an exploratory analysis involving muscular function, respiratory function and muscle strength.

Once Unite-CNM study is completed, the company will analyse a potentially registration-directed Phase II/III study on all age groups.

Dynacure is developing DYN101 in collaboration with Ionis Pharmaceuticals, a company known for its RNA-targeted drug discovery.

Preclinical efficacy of the medicine was observed in multiple mouse models of the disease.

Dynacure chief medical officer Chris Freitag said: “We are committed to providing CNM patients and their families with a therapeutic solution to treat this devastating, progressive muscle disease. Today, we are pleased to have made progress toward this goal with the first dose of DYN101 in a patient in our Phase I/II ‘Unite-CNM’ study.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena